Connect with us

Healthcare

Lupin Limited (lupin) Secures U.S. FDA Approval for Pitolisant Tablets

Lupin Limited (LUPIN) receives U.S. FDA approval for Pitolisant Tablets, marking a significant milestone in its pharmaceutical portfolio.

Manas shah, Analyst — IT & Software

Published

on

Lupin Limited LUPIN FDA Approval August 2026

Lupin Limited (LUPIN) today announced that it has received the final approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Pitolisant Tablets, 4.45 mg and 17.8 mg. The U.S. FDA has approved Lupin’s Pitolisant Tablets, 4.45 mg and 17.8 mg, as bioequivalent to Wakix® for the indications in the approved labeling. This approval marks a significant milestone for Lupin, expanding its pharmaceutical portfolio in the U.S. market.

Strategic Expansion

Lupin Limited, a global pharmaceutical leader, specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company enjoys a strong position in India and the U.S. across multiple therapy areas. This approval will allow Lupin to offer its Pitolisant Tablets to patients in need, thereby enhancing its contribution to global healthcare.

Company’s Commitment

Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. With 15 state-of-the-art manufacturing sites and 6 research centers globally, the company continues to innovate and expand its market presence. The FDA approval for Pitolisant Tablets is a testament to Lupin’s dedication to quality and patient care.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Lupin Limited

Lupin Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

LUPIN
Healthcare › Drug Manufacturers - Specialty & Generic
APPROACHING RESISTANCE
84
Fundamental
54
Technical
69
Overall

1W -0.39%
1M +1.39%
3M -11.4%
P/E: 17.5 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Lupin moves sideways over three months, with neither buyers nor sellers taking control. The PEG of 0.14 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.1% and profits at 131.5% CAGR. That is strong double-digit growth on both counts. RSI stands at 30, well into oversold territory. Yet sellers still dominated on 21 of recent sessions versus 9 for buyers, so the pressure has not fully lifted. Revenue grows at 19.1% and profits at 131.5%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Lupin Limited.

Healthcare

Themis Medicare Limited (themismed) Q2 FY27: Revenue Up 15%, Ebitda Positive

Themis Medicare Limited (THEMISMED) reports a 15% revenue increase in Q2 FY27, with EBITDA turning positive at 6.2% margin.

shalini shishodia tradealone

Published

on

Themis Medicare Limited Themismed Q2 FY27 Results

Themis Medicare Limited (THEMISMED) has announced its financial results for Q2 FY27, showcasing a strong turnaround with a 15.1% year-on-year revenue growth to ₹89.74 crore. This performance was led by a remarkable 71% rebound in the API business to ₹20 crore, while the Formulations business maintained steady revenue at ₹69 crore.

Financial Highlights

The company reported a return to operating profitability with an EBITDA of ₹5.58 crore at a 6.2% margin, compared to a loss in the year-ago quarter. The net profit after tax (PAT) stood at ₹7.06 crore against a loss last year. This improvement is attributed to the company’s focus on productivity and operational efficiency.

Segment Performance

Within Formulations, the Critical Care Division doubled its profit before tax (PBT) during the quarter, driven by Themiseal Gel’s encouraging month-on-month momentum. The Ortho and Gynecology Division also doubled its revenue, bolstered by strong traction in the hormonal portfolio and the integrated product strategy. The API business demonstrated a robust recovery, gaining healthy revenue visibility.

For H1 FY27, revenue stood at ₹176.70 crore, with the strong performance in Q2 helping offset a more challenging first quarter. The company remains optimistic about the second half of the year, supported by continued operational efficiencies, stronger field productivity, disciplined cost management, and a sustained recovery in the API business.

Dr. Sachin Patel, Managing Director & CEO, commented, “Q2 FY27 reflects a strong turnaround for the Company. We are pleased to report a return to operating profitability, with EBITDA of ₹5.58 crore at a 6.2% margin, compared with a loss in the year-ago quarter, and PAT of ₹7.06 crore against a loss last year. This improvement comes even as we continue to optimize our inventory pricing and cost structure and gives us confidence that our focus on productivity and operational efficiency is delivering results.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Themis Medicare Limited

Themis Medicare Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

THEMISMED
Healthcare › Drug Manufacturers - Specialty & Generic
APPROACHING SUPPORT
36
Fundamental
44
Technical
40
Overall

1W -0.35%
1M -6.69%
3M -3.77%
P/E: 23.3 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Themis moves sideways over three months, with neither buyers nor sellers taking control. Revenue contracts at -0.4% CAGR. That signals structural headwinds, not a short-term blip. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI stands at 31, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at -0.4% yet the PEG reaches 99.00 — expensive for that growth. Furthermore, the stock drops 3.8% in three months. Neither value nor momentum supports this setup. It needs an earnings beat or a price reset first. Check Fundamentals of Themis Medicare Limited.

Continue Reading

GUJTHEM

Gujarat Themis Biosyn Limited Q2 FY27: Revenue Up 12% Yoy, New Facility Commissioned

Gujarat Themis Biosyn Limited (GUJTHEM) reports Q2 FY27 revenue up 12% YoY, new fermentation facility commissioned.

shalini shishodia tradealone

Published

on

Gujarat Themis Biosyn Limited Gujthem Q2 FY27 Results

Gujarat Themis Biosyn Limited (GUJTHEM) has reported robust financial results for Q2 FY27, with standalone revenue growing 12% year-on-year to Rs. 47.5 crore. The growth was primarily driven by strong volume momentum and a favorable shift in product mix towards Active Pharmaceutical Ingredients (APIs). The company’s new fermentation facility, commissioned during the quarter, marks a significant milestone in strengthening its manufacturing capabilities. Although the commissioning phase has had a near-term impact on operating margins, benefits from augmented capacity utilization are expected to become increasingly visible from Q4 FY27 onwards.

Quarterly Financial Highlights

During Q2 FY27, the company’s EBITDA stood at Rs. 8.5 crore, down 15.3% year-on-year, while EBITDA margins decreased by 1,210 basis points to 17.8%. The profit after tax (PAT) was Rs. 8.5 crore, down 40.6% YoY, with PAT margins dropping by 1,584 basis points to 17.8%. The company’s earnings per share (EPS) stood at Rs. 0.65 compared to Rs. 1.31 in the same quarter last year.

Half-Yearly Financial Performance

For H1 FY27, the company’s revenue grew 17% year-on-year to Rs. 91 crore. EBITDA increased 11% to Rs. 39 crore, while EBITDA margins declined by 235 basis points to 42.2%. The PAT for H1 FY27 was Rs. 19.5 crore, down 16.3% YoY, with PAT margins decreasing by 841 basis points to 21.4%. The EPS for H1 FY27 was Rs. 1.50 compared to Rs. 2.14 in the same period last year.

Dr. Sachin Patel, Managing Director, commented on the results, stating, ‘We are pleased to have commenced FY27 with healthy business momentum. As the new capacity moves towards higher utilization and the benefits of the acquisition begin to flow through, we expect operating performance to strengthen progressively. Our strategic priorities remain centered around precision fermentation, bioconversion, gene therapy, anti-infectives, and biopeptides, supported by capacity utilization, R&D-led product development, and a continued focus on operational efficiency. We believe these initiatives provide a strong platform for sustainable growth and value creation over the medium to long term.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

GUJTHEM
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING UP
52
Fundamental
60
Technical
56
Overall

1W +2.22%
1M -0.13%
3M +11.44%
P/E: 86.2 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Gujarat posts a 11.4% three-month gain, but softens in the last few weeks. Industry-leading margins of 28.0% reflect exceptional pricing power and operational efficiency. Revenue contracts at 3.8% CAGR. That signals structural headwinds, not a short-term blip. The stock gives back 0.1% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 3.8% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Gujarat Themis Biosyn Limited.

Continue Reading

Healthcare

Zydus Lifesciences Limited (zyduslife) Inspection by USFDA Concludes at Liqmeds, UK

Zydus Lifesciences Limited (ZYDUSLIFE) announces the closure of USFDA inspection at LiqMeds, UK with 4 observations.

Deputy Editor, Equities for tradealone

Published

on

Zydus Lifesciences Limited Zyduslife Inspection by USFDA

Zydus Lifesciences Limited (ZYDUSLIFE) announced the closure of a USFDA inspection at LiqMeds, UK. The inspection took place from 9th to 13th November 2026 and concluded with four observations. The company will work closely with the USFDA to address these observations expeditiously.

Inspection Details

The USFDA conducted an inspection at LiqMeds, UK, focusing on compliance and operational standards. The four observations noted during the inspection will be addressed promptly to ensure full compliance with regulatory requirements.

Company’s Response

Zydus Lifesciences Limited is committed to maintaining high standards of quality and compliance. The company will collaborate closely with the USFDA to resolve the observations identified during the inspection. This proactive approach aims to expedite the resolution process and uphold the company’s reputation for quality and integrity.

As a result, Zydus Lifesciences Limited remains focused on its mission to deliver high-quality pharmaceutical products globally. The company’s dedication to addressing regulatory observations underscores its commitment to continuous improvement and adherence to international standards.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

ZYDUSLIFE
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING DOWN
86
Fundamental
62
Technical
75
Overall

1W -0.67%
1M +5.8%
3M +4.82%
P/E: 28.6 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.67 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock trades at 70% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.

Continue Reading

Trending